The U.S. Federal Trade Commission (FTC) is looking into whether baby-formula makers, including Abbott Laboratories (NYSE:ABT), Reckitt Benckiser (OTC:RBGLY), and Nestlé...
Abbott (ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter, Sensor Enabled™, the world's first ablation...
The Dow has technically entered a bull market after Jerome Powell's comments yesterday Still, those that want to play the rebound should keep in mind that macro risks remain Here...
Many growth stocks and exchange-traded funds (ETFs) are currently changing hands around 52-week or even multi-year lows and the impending earnings season could bring more...
The US Federal Reserve has recently delivered its most significant interest rate hike since 1994 to counter four-decade high inflation, pushing the S&P 500 deeper into bear market...
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its Established Pharmaceutical Products segment includes gastroenterology products, women’s health products, cardiovascular and metabolic products, pain and central nervous system products and respiratory drugs and vaccines. Its Diagnostic Products segment includes core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion medicine; molecular diagnostics polymerase chain reaction (PCR) instrument systems; point of care systems; rapid diagnostics lateral flow testing products, and informatics and automation solutions. Its Nutritional Products segment includes various forms of infant formula and follow-on formula, adult and other pediatric nutritional products and others.
|Average||124.05 (+19.54% Upside)|
|No. of Analysts||20|